HPV関連疾患市場：適応症別、治療法別、流通別-2025-2030年の世界予測

HPV関連疾患市場は、2023年に93億米ドルと評価され、2024年には98億4,000万米ドルに達すると予測され、CAGR 6.13％で成長し、2030年には141億1,000万米ドルに達すると予測されています。

HPV関連疾患市場には、子宮頸がん、口腔咽頭がん、肛門がん、性器いぼなど、ヒトパピローマウイルス（HPV）によって引き起こされる疾患の診断、治療、予防が含まれます。この市場の必要性は、世界のHPV感染の高い有病率と、がんおよびがん以外の疾患との関連性によって強調されており、強固なスクリーニングプログラム、ワクチン、治療薬が必要とされています。最終用途は、医療提供者、病院、研究機関であり、予防および治療ソリューションを求める個人患者です。主な成長要因としては、HPV関連の健康リスクに対する意識の高まり、ワクチン接種プログラムの拡大、分子診断の技術的進歩、予防対策に対する政府や組織の強力な支援などが挙げられます。最新のビジネスチャンスは、HPVワクチンの普及、より効率的な診断法の開発、新興経済諸国におけるヘルスケア支出の増加にあります。企業は、次世代ワクチンの研究開発、個別化医療へのアプローチ、HPV関連ヘルスケア資源への世界のアクセス改善などに投資することで、こうした機会を捉えることができると思われます。とはいえ、低所得地域における財政的制約、ワクチン接種へのためらい、HPVとそのワクチンに関する誤った情報、ワクチンとヘルスケアへのアクセス格差といった制約が市場成長の妨げとなっています。課題には、規制上のハードルや、検診・診断精度の向上に対する継続的なニーズも含まれます。技術革新が必要な分野には、ワクチンの有効性と送達の強化、ポイントオブケア診断検査の開発、HPV関連疾患の進行を予測・管理するための人工知能の活用などがあります。市場の特性に関する考察では、技術的なブレークスルーが頻繁に起こる競合情勢が浮き彫りになっており、持続的な成長にはイノベーションの早期導入と戦略的提携が不可欠です。企業にとっては、政府や非政府の医療機関との協力関係を育み、誤った情報に対抗するための教育キャンペーンに注力することが、市場へのリーチと影響力を拡大するための戦略として推奨されます。

市場力学：急速に進化するHPV関連疾患市場の主要市場インサイトを公開

HPV関連疾患市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • HPV関連疾患の有病率の上昇
  • 標的治療の成長と発展
  • HPV感染症の啓発に対する政府の積極的な支援とイニシアチブ
• 市場抑制要因
  • HPVに関連する副作用
• 市場機会
  • がん研究への資金援助と投資の増加
  • HPV共同検査の技術的進歩の高まり
• 市場の課題
  • 複数の治療オプションに関する患者の認識不足

ポーターの5つの力：HPV関連疾患市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：HPV関連疾患市場における外部からの影響の把握

外部マクロ環境要因は、HPV関連疾患市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析HPV関連疾患市場における競合情勢の把握

HPV関連疾患市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスHPV関連疾患市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、HPV関連疾患市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨HPV関連疾患市場における成功への道筋を描く

HPV関連疾患市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • HPV関連疾患の罹患率の上昇
    • 標的治療の成長と発展
    • HPV疾患の啓発に向けた政府の積極的な支援と取り組み
  • 抑制要因
    • HPVに関連する副作用
  • 機会
    • がん調査への資金と投資の増加
    • HPVの同時検査における技術の進歩
  • 課題
    • 複数の治療オプションに関する患者の認識不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 HPV関連疾患市場適応症別

• アイン
• 肛門がん
• 子宮頸がん
• シン
• 性器イボ

第7章 HPV関連疾患市場セラピー

• 防止
• 治療

第8章 HPV関連疾患市場配布元

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカのHPV関連疾患市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のHPV関連疾患市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのHPV関連疾患市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alembic Pharmaceuticals
• AstraZeneca plc
• Bausch Health Companies Inc
• Biocon Ltd.
• Bristol-Myers Squibb Co.
• Eli Lilly and Company.
• F. Hoffmann-La Roche Ltd
• GEA Group Aktiengesellschaft
• GlaxoSmithKline plc
• Inovio Pharmaceuticals, Inc.
• J.M. Huber Corporation
• Johnson & Johnson Services, Inc.
• KinoPharma, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.

LIST OF FIGURES

• FIGURE 1. HPV ASSOCIATED DISORDERS MARKET RESEARCH PROCESS
• FIGURE 2. HPV ASSOCIATED DISORDERS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HPV ASSOCIATED DISORDERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HPV ASSOCIATED DISORDERS MARKET DYNAMICS
• TABLE 7. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY AIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY ANAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 32. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 49. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 52. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 104. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 116. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 147. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2023

The HPV Associated Disorders Market was valued at USD 9.30 billion in 2023, expected to reach USD 9.84 billion in 2024, and is projected to grow at a CAGR of 6.13%, to USD 14.11 billion by 2030.

The HPV associated disorders market encompasses the diagnosis, treatment, and prevention of diseases caused by the human papillomavirus (HPV), including cervical, oropharyngeal, and anal cancers, as well as genital warts. The necessity of this market is underscored by the high prevalence of HPV infections worldwide and their association with cancerous and non-cancerous conditions, necessitating robust screening programs, vaccines, and therapeutics. The application extends to healthcare providers, hospitals, and research institutions, while the end-use scope covers individual patients seeking preventative and therapeutic solutions. Key growth factors include increasing awareness about HPV-related health risks, expanding vaccination programs, technological advancements in molecular diagnostics, and strong government and organizational support for preventative measures. The latest opportunities lie in the exploitation of HPV vaccines' rising acceptance, ongoing development of more efficient diagnostic methods, and increased healthcare spending in emerging economies. Companies could seize these opportunities by investing in R&D for next-generation vaccines, personalized medicine approaches, and improving access to HPV-related healthcare resources globally. Nonetheless, market growth is hampered by limitations such as financial constraints in low-income regions, vaccine hesitancy, misinformation about HPV and its vaccines, and disparities in vaccine and healthcare access. Challenging factors also include regulatory hurdles and the ongoing need to enhance screening and diagnostic accuracy. Areas ripe for innovation include enhancing the efficacy and delivery of vaccines, developing point-of-care diagnostic tests, and leveraging artificial intelligence to predict and manage HPV-associated disease progression. Insights into the market's nature highlight a competitive landscape with frequent technological breakthroughs, making early adoption of innovations and strategic partnerships crucial for sustained growth. For businesses, fostering collaborations with governmental and non-governmental health organizations and focusing on educational campaigns to combat misinformation are recommended strategies to widen market reach and impact.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HPV Associated Disorders Market

The HPV Associated Disorders Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of HPV related diseases
  • Growth and development in targeted therapies
  • Proactive government support and initiatives for HPV disorders awareness
• Market Restraints
  • Adverse effects associated with HPV
• Market Opportunities
  • Increased funding and investment for cancer research
  • Growing technological advancement in HPV co-testing
• Market Challenges
  • Lack of patient awareness regarding several treatments options

Porter's Five Forces: A Strategic Tool for Navigating the HPV Associated Disorders Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HPV Associated Disorders Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HPV Associated Disorders Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HPV Associated Disorders Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HPV Associated Disorders Market

A detailed market share analysis in the HPV Associated Disorders Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HPV Associated Disorders Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HPV Associated Disorders Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HPV Associated Disorders Market

A strategic analysis of the HPV Associated Disorders Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HPV Associated Disorders Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals, AstraZeneca plc, Bausch Health Companies Inc, Biocon Ltd., Bristol-Myers Squibb Co., Eli Lilly and Company., F. Hoffmann-La Roche Ltd, GEA Group Aktiengesellschaft, GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., J.M. Huber Corporation, Johnson & Johnson Services, Inc., KinoPharma, Inc., Merck & Co., Inc., Novartis AG, and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the HPV Associated Disorders Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indication, market is studied across AIN, Anal Cancer, Cervical Cancer, CIN, and Genital Warts.
• Based on Therapy, market is studied across Prevention and Treatment.
• Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of HPV related diseases
    • 5.1.1.2. Growth and development in targeted therapies
    • 5.1.1.3. Proactive government support and initiatives for HPV disorders awareness
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse effects associated with HPV
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased funding and investment for cancer research
    • 5.1.3.2. Growing technological advancement in HPV co-testing
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of patient awareness regarding several treatments options
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. HPV Associated Disorders Market, by Indication

• 6.1. Introduction
• 6.2. AIN
• 6.3. Anal Cancer
• 6.4. Cervical Cancer
• 6.5. CIN
• 6.6. Genital Warts

7. HPV Associated Disorders Market, by Therapy

• 7.1. Introduction
• 7.2. Prevention
• 7.3. Treatment

8. HPV Associated Disorders Market, by Distribution

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas HPV Associated Disorders Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific HPV Associated Disorders Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa HPV Associated Disorders Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alembic Pharmaceuticals
• 2. AstraZeneca plc
• 3. Bausch Health Companies Inc
• 4. Biocon Ltd.
• 5. Bristol-Myers Squibb Co.
• 6. Eli Lilly and Company.
• 7. F. Hoffmann-La Roche Ltd
• 8. GEA Group Aktiengesellschaft
• 9. GlaxoSmithKline plc
• 10. Inovio Pharmaceuticals, Inc.
• 11. J.M. Huber Corporation
• 12. Johnson & Johnson Services, Inc.
• 13. KinoPharma, Inc.
• 14. Merck & Co., Inc.
• 15. Novartis AG
• 16. Pfizer, Inc.